Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

NCT07151508 · clinicaltrials.gov ↗

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Neterton Syndrome

Interventions

DEVICE: Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology